TXMD - TherapeuticsMD prices $110M public offering

TherapeuticsMD (TXMD) has priced an underwritten public offering of 59.5 million shares for net proceeds of $110M.Proceeds to be used for commercialization of its three FDA-approved products, Imvexxy, Bijuva, and Annovera; partial proceeds also for offering to discharge certain indebtedness currently outstanding under its financing agreement and if any remaining for general corporate purposes.The company has granted underwriters a 30-day option to purchase up to an additional 8.9M shares.Cantor Fitzgerald is acting as sole book-runner.TherapeuticsMD shares are down 10.6% to $1.94 in morning trading.

For further details see:

TherapeuticsMD prices $110M public offering